Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin

Gastric Cancer

Volumn 12, Issue 4, 2009, Pages 206-211

  Shimoyama, Rai ^a,b   Yasui, Hirofumi ^a   Boku, Narikazu ^a   Onozawa, Yusuke ^a   Hironaka, Shuichi ^a   Fukutomi, Akira ^a   Yamazaki, Kentaro ^a   Taku, Keisei ^a   Kojima, Takashi ^a   Machida, Nozomu ^a   Todaka, Akiko ^a   Tomita, Hideharu ^a   Sakamoto, T Akeshi ^a   Tsushima, Takahiro ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b Shonankamakura General Hospital   (Japan)

Author keywords

Metastatic gastric cancer; Third line chemotherapy; Weekly paclitaxel

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; GRANISETRON; IRINOTECAN; PACLITAXEL; RANITIDINE; UFT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASCITES; BONE METASTASIS; CANCER RECURRENCE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVARY METASTASIS; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; SENSORY NEUROPATHY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; DRUG RESISTANCE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SALVAGE THERAPY; STOMACH TUMOR; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASCITES; CAMPTOTHECIN; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949900399     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-009-0524-9     Document Type: Article

References (29)

1. Parki DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
2. Statistics and Information Department, Ministry of Health, Labour and Welfare. Vital statistics in 2007 (in Japanese). http://www.mhlw.go.jp/. Accessed 30 April 2009.
3. Pyrhoenen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
4. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41. (Pubitemid 23182046)
5. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoeden PO Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 1994;5:189-90. (Pubitemid 24062577)
6. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol 2007; 25 (18S) : LBA4513.
7. Koizumi W, Narahara H, Hara T, Takagane T, Takagi M, Miyashita K, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial) : a phase III trial. Lancet Oncol 2008;9:215-21.
8. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998;4:269-74. (Pubitemid 28354929)
9. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordano P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998;9:307-10. (Pubitemid 28241819)
10. Ohtsu A, Boku N Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-9. (Pubitemid 28366916)
11. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-7. (Pubitemid 32834495)
12. Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, et al. Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response: Semin Oncol 1996; 23 (6 Suppl 16) : 128-35. (Pubitemid 27069005)
13. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92. (Pubitemid 27020572)
14. Rosenberg P, Anderson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al: Randomized trial of single agent paclitaxel given weekly versus every 3 weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta Oncol 2002;41:418-24. (Pubitemid 35222039)
15. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol 2008;26:1642-49.
16. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998;16:153-8. (Pubitemid 28041593)
17. Cho H, Shotsu A, Konishi K, Kanari M, Tsuburaya A, Kobayasi O, et al. Weekly paclitaxel for the second-line treatment of recurrent and advanced gastric cancer (RAGC). Proc Am Soc Clin Oncol 2002; 21 (abstract 2365).
18. Arai T, Hamaguchi T, Shirao K, Yamada Y, Muro K, Matsumura Y, et al. Weekly paclitaxel in patients with heavily treated advanced gastric cancer. Proc Am Soc Clin Oncol 2003; 22 (abstract 1291).
19. Arai T, Hamaguchi T, Shirao K, Shimada Y, Yamada Y, Muro K, et al. Weekly paclitaxel (PTX) in patients with heavily treated advanced gastric cancer (AGC). Jpn J Cancer Clin 2003;49:621-5.
20. Emi Y, Kakeji Y, Baba H, Ishida T, Maehara Y. Weekly paclitaxel therapy as second-line therapy for advanced, recurrent stomach cancer. Jpn J Cancer Clin 2004;50:277-81.
21. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshimo T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006;9:14-8.
22. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG 0302 study). Anticancer Res 2007;27:2667-72. (Pubitemid 47227980)
23. Emi Y, Yamamoto M, Takahashi I, Orita H, Kakeji Y, Kohnoe S, et al. Phase II study of weekly paclitaxel by 1-hour infusion for advanced gastric cancer. Surg Today 2008;38:1013-20.
24. Japanese translation of common terminology criteria for adverse events (CTCAE), and instructions and guidelines. Int J Clin Oncol 2004; 9 (Suppl 3) : 1-82.
25. Gehan EA, Tefft MC. Will there be resistance to the RECIST (response evaluation criteria in solid tumors) ? J Natl Cancer Inst 2000;92:179-81.
26. Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, et al. Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. World J Gastroenterol 2006;12:1412-5
27. Ishida T, Shimokawa H, Kawaguchi K, Nose N, Ikegami T, Itoh H, et al. Effective weekly paclitaxel administration for gastric cancer with malignant ascites: a case report (in Japanese). Jpn J Cancer Chemother (Gan To Kagaku Ryoho) 2002;29:1643-46.
28. Hikino H, Yamada T, Hata T, Nakamura K, Sugimoto S, Kanazawa A, et al. Efficacy of weekly administration of paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination. Jpn J Cancer Chemother 2004;31:759-61.
29. Kojima T, Matsui T, Uemura T, Fujimitsu Y, Kato J, Kojima H. A case of advanced gastric cancer treated with weekly paclitaxel with measurement of concentrations in blood and ascites. Jpn J Cancer Chemother 2003;30:1529-31.